Compare TKLF & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | APVO |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 8.3M |
| IPO Year | 2020 | 2023 |
| Metric | TKLF | APVO |
|---|---|---|
| Price | $2.33 | $4.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.7K | ★ 34.1K |
| Earning Date | 12-19-2025 | 05-13-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.25 |
| 52 Week High | $4.32 | $13.11 |
| Indicator | TKLF | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 47.62 |
| Support Level | $2.00 | $3.88 |
| Resistance Level | $2.41 | $7.65 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 7.83 | 55.46 |
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.